Search
Haloprogin
go.drugbank.com/drugs/DB00793ApprovedWithdrawnHaloprogin is used as a topical ointment or cream in the treatment of Tinea infections. … Haloprogin is no longer available in the United States and has been discontinued.
Enrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedDue to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry. … Enrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use.
CGC-11047
go.drugbank.com/drugs/DB05722InvestigationalCGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalIdraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.
Isoflurane
go.drugbank.com/drugs/DB00753ApprovedInvestigationalVet approvedA stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
OSI-461
go.drugbank.com/drugs/DB05415InvestigationalOSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Sulodexide
go.drugbank.com/drugs/DB06271ApprovedInvestigationalWithdrawnSulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
IN01
go.drugbank.com/drugs/DB16434ExperimentalOf note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.
NCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.